Edgar Filing: Naru Sarath - Form 4

Naru Sarath										
Form 4 February 16,	2007									
								OMB A	PPROVAL	
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							3235-0287			
Check thi							Expires:	January 31,		
subject to Section 10 Form 4 or	if no longer subject to Section 16. Form 4 or					Estimated a burden hou response	irs per			
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type R	Responses)									
1. Name and A Naru Sarath	Symbol	2. Issuer Name and Ticker or Trading Symbol TRANS-INDIA ACQUISITION				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
		CORP	[TIL]				(Clied	k an applicable	-	
			3. Date of Earliest Transaction (Month/Day/Year)			X DirectorX 10% Owner Officer (give title Other (specify below) below)				
CORPORAT	S-INDIA ACQUI ΓΙΟΝ, 300 SOUT DRIVE, SUITE 1	TH	2007				UCIOW)	below)		
(Street) 4. If Amendment, Da			e Original 6. Individual or Jo				int/Group Filing(Check			
			onth/Day/Year)	h/Day/Year) Applic _X_F				olicable Line) _ Form filed by One Reporting Person		
CHICAGO, IL 60606			Person				•	rm filed by More than One Reporting		
(City)	(State)	(Zip) Tal	ble I - Non-D	erivative S	Securit	ties Acc	quired, Disposed of	f, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Code	4. Securities Acquired ion(A) or Disposed of (D) (Instr. 3, 4 and 5) (A)			6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
C			Code V	Amount	or (D)	Price	(Instr. 3 and 4)		C	
Common Stock	02/14/2007		Р	63,331 (1)	А	<u>(2)</u>	813,331	Ι	See footnote (4)	
Reminder: Repo	ort on a separate line	for each class of sec	urities benefi	cially own	ed dire	ectly or	indirectly.			
							ond to the collec ned in this form		SEC 1474 (9-02)	

information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Naru Sarath - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exerc Expiration D (Month/Day/	ate	7. Title and A Underlying S (Instr. 3 and	Securities	8 I S (
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Warrant (Right to Buy)	\$ 5	02/14/2007		Р	63,331 (1)	(3)	02/08/2012	Common Stock	63,331	

Reporting Owners

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
Varu Sarath 2/O TRANS-INDIA ACQUISITION CORPORATION 00 SOUTH WACKER DRIVE, SUITE 1000 2'HICAGO, IL 60606	Х	Х			
lianatures					

N C 3 C

/s/ Craig Colmar, Attorney-in-fact	02/15/2007		
<u>**</u> Signature of Reporting Person	Date		

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The reported securities are Units of Trans-India Acquisition Corporation, each Unit consisting of one share of common stock and one (1)warrant to purchase one share of common stock.
- The cost of the entire Unit is \$8.00 per Unit. (2)
- The warrants will become exercisable on the latter of (i) the completion of a business combination with a target business and (ii) February (3)8, 2008.

By Marillion Pharmaceuticals India Pvt. Ltd. Mr. Naru is an officer of Marillion Pharmaceuticals India Pvt. Ltd. and has an indirect pecuniary interest in the securities held by such entity. Mr. Naru disclaims beneficial ownership of the securities held by Marillion

(4) Pharmaceuticals India Pvt. Ltd., and the filing of this report is not an admission that Mr. Naru is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Remarks:

Exhibit List: Exhibit 24 Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Γ S